Bausch + Lomb (NYSE:BLCO) Price Target Cut to $18.00 by Analysts at Stifel Nicolaus

Bausch + Lomb (NYSE:BLCO) had its price objective reduced by investment analysts at Stifel Nicolaus from $19.00 to $18.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 3.42% from the stock’s current price.

A number of other research firms have also weighed in on BLCO. Citigroup lowered Bausch + Lomb from a “buy” rating to a “neutral” rating and decreased their price target for the company from $24.00 to $22.00 in a research report on Wednesday, December 11th. Royal Bank of Canada upped their price target on shares of Bausch + Lomb from $20.00 to $23.00 and gave the company an “outperform” rating in a research report on Tuesday, October 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a research report on Thursday, October 31st. Bank of America restated an “underperform” rating and issued a $18.00 target price on shares of Bausch + Lomb in a report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Bausch + Lomb in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Bausch + Lomb currently has an average rating of “Hold” and a consensus target price of $20.33.

Bausch + Lomb Trading Down 0.3 %

Shares of NYSE:BLCO opened at $17.41 on Wednesday. Bausch + Lomb has a twelve month low of $13.16 and a twelve month high of $21.69. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The firm has a market cap of $6.13 billion, a P/E ratio of -16.58, a P/E/G ratio of 2.17 and a beta of 0.47. The company has a 50 day moving average of $18.41 and a 200-day moving average of $18.14.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the firm posted $0.22 earnings per share. The company’s revenue was up 18.8% on a year-over-year basis. As a group, analysts anticipate that Bausch + Lomb will post 0.6 earnings per share for the current fiscal year.

Institutional Trading of Bausch + Lomb

A number of institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. raised its stake in shares of Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock valued at $48,000 after acquiring an additional 1,004 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Bausch + Lomb in the 4th quarter worth approximately $72,000. Squarepoint Ops LLC acquired a new position in Bausch + Lomb during the 2nd quarter valued at $173,000. Gordian Capital Singapore Pte Ltd bought a new stake in shares of Bausch + Lomb in the third quarter valued at about $289,000. Finally, Polar Asset Management Partners Inc. acquired a new position in Bausch + Lomb in the 3rd quarter valued at approximately $289,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.